Entero Healthcare Solutions Ltd

Dematerialisation status

• RTA confirms no dematerialisation/rematerialisation requests received during July 2026 to September 2026.

Entero Healthcare Solutions Limited: Trading Window closed from October 01, 2026 until up to 48 (Forty Eight) hours after declaration of the Unaudited Financial Results of the Company for the quarter ended September 30, 2026

Meeting Details

• Date and time: September 29, 2026 at 2:00 PM onwards.
• Type/Mode: Group meeting, virtual.
• Organiser: Arihant Capital Markets Ltd.
• Purpose: discuss publicly available information; general investor interaction.
• Key company participants: Vice President – Group General Counsel, Company Secretary & Compliance Officer.

Key disclosures

• Target company: Entero Healthcare Solutions Ltd
• Disclosing party: Surbhi Singh and Prasid Uno Family Trust; not promoter group
• Transaction type: disposal of voting-rights shares
• Pre-holding: voting rights 29,14,920 (6.70%), encumbrances 5,40,500 (1.24%), total 34,55,420 (7.94%)
• Total shares sold: 21,30,000 (4.89% voting, 4.87% diluted)
• Sale on stock exchange: 7,40,000 shares via Bulk Deal on 17 Sep 2026
• Sale on stock exchange: 13,90,000 shares via Block Deal on 18 Sep 2026
• Post-holding: voting rights 7,84,920 (1.81%), encumbrances 5,40,500 (1.24%), total 13,25,420 (3.05%), diluted 4,37,18,962
• Date of transactions: 17 Sep 2026 and 18 Sep 2026
• Equity capital before/after: INR 43,52,30,720; 4,35,23,072 shares; diluted 4,37,18,962

Regulatory penalty on subsidiary

• GST Authority levied Rs 12,91,728 penalty on ACE Cardiopathy Solutions Private Limited for non-generation of E-Invoice.
• Penalty paid under protest to secure immediate vehicle release and avoid demurrage.
• Date of order/receipt: 11 September 2026.
• Impact: amount not material to Entero's consolidated financials; recovery/refund pursued.

Meeting Details

• Date and time: September 02, 2026, 03:00 P.M. onward.
• Type: 1x1 / group meeting; Mode: Physical.
• Organized by: Elara Capital.
• Location: Mumbai.
• Key company participants: officials of the company attending.
• Purpose: investor interaction based on publicly available information.

Director tenure end

• Tenure of Rajesh Shashikant Dalal, Non-Executive Independent Director, ends Aug 24, 2026; ceases NRC/SRC chairmanship; Audit Committee seat.

AGM Details

• AGM held on 19 August 2026 at 12:30 IST via VC/OAVM.
• AGM concluded at 1:25 PM IST.
• Record/cut-off date: 12 August 2026.

Key Resolutions

• Ordinary: Adopt standalone financial statements for year ended 31 March 2026.
• Ordinary: Adopt consolidated financial statements for year ended 31 March 2026.
• Ordinary: Re-appoint a director by rotation.
• Special: Remuneration to MD & CEO for remaining tenure.
• Special: Remuneration to Whole-Time Director & COO for remaining tenure.
• Special: Re-appointment of independent director for second term.
• Special: Re-appointment of another independent director for second term.

Voting Results

• Resolution 1 passed; 99.9996% in favour, 0.0004% against.
• Resolution 2 passed; 99.9996% in favour, 0.0004% against.
• Resolution 3 passed; 99.9005% in favour, 0.0995% against.
• Resolution 4 passed; 93.5766% in favour, 6.4234% against.
• Resolution 5 passed; 93.9466% in favour, 6.0534% against.
• Resolution 6 passed; 94.3368% in favour, 5.6632% against.
• Resolution 7 passed; 94.3467% in favour, 5.6533% against.

Director Changes

• Ordinary resolution to re-appoint director by rotation.
• No new director appointments announced.

Auditors

• Statutory auditors’ report read; no qualifications.
• No changes to auditor appointments announced.

Financial Performance

• Consolidated revenue: INR 1,940 crores; up 38.2% YoY; like-for-like +40%.
• Gross margin 11.4%; up 147 bps YoY.
• EBITDA margin 5.0%; up 143 bps YoY; EBITDA growth ~94% YoY.
• PAT: INR 52 crores; up 72% YoY; PAT margin 2.7%.
• PAT to owners: INR 38 crores; up 37%; non-controlling interest INR 14 crores (27% of PBT).
• Net working capital days: 61 vs 66 previously; ROCE 21.1%; ROE 20.4%.

Operating Update

• MedTech is a key margin lever; higher gross and EBITDA margins vs pharma distribution.
• MedTech organic revenue target: cross INR 1,000 crores in FY27.
• Scale metrics: 72,000 retail customers, 2,300 hospital customers, 83,400 SKUs, 138 warehouses across 475 districts in 19 states.
• Organic quarterly growth: 17.8% reported, 19.6% like-for-like; inorganic growth 20.4% via calendarization.
• FY27 guidance: consolidated revenue growth ~23% YoY; EBITDA margin 5%; EBITDA-to-OCF 50%.

Balance Sheet and Cash Flow

• Subsidiaries funded via inter-company deposits/loans; cash flow repaid to parent to fund acquisitions.
• Non-wholly owned subsidiaries have defined path to acquire residual stake; horizon 2–5 years.
• Debt for acquisitions: about INR 200 crores; interest costs expected to stay in the same range.
• Balance sheet numbers are not quarterly audited; disclosures in September (biannual process).
• Minority share of profit reinvested in the business, not paid out.

Projects and Capex

• Depreciation run-rate expected to stay broadly in current level unless major new capex occurs.
• No major FY27 acquisitions planned; existing pipeline noted but focus remains organic.
• Defined minority buyout mechanics exist; typical horizon 2–5 years.

Guidance and Outlook

• FY27 guidance reiterated: ~23% revenue growth; 5% EBITDA margin; 50% EBITDA-to-OCF conversion.
• MedTech revenue target reaffirmed: organic growth path to cross INR 1,000 crores in FY27.
• Longer-term view: MedTech and platform scale to drive margin and ROCE expansion; returns seen improving.

Q&A Highlights

• Near-term inorganic pace muted; internal target to grow >20% organically over 3–4 years.
• ROCE target ~25–30% if no further acquisitions; EBITDA margins improve with scale and MedTech mix.
• Cash from subsidiaries via inter-company loans funds additional acquisitions; balance-sheet discipline maintained.
• No major FY27 acquisitions; pipeline exists; management prioritizes organic growth.
• IPM cyclicality: Q2 historically strongest; long-run IPM growth in 10–12% range; quarterly mix varies.
• Debt cost impacted by acquisition financing; interest costs expected to stay broadly in current range.

Meeting Details

• Quarter ended June 30, 2026 unaudited results earnings call.
• Type: group earnings call; mode: virtual conference.

Additional Notes

• Audio recording uploaded; transcript to be shared with stock exchanges and posted on the company website.